These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 17084083)

  • 1. Towards erythropoietin mimicking small molecules.
    Dömling A; Beck B; Baumbach W; Larbig G
    Bioorg Med Chem Lett; 2007 Jan; 17(2):379-84. PubMed ID: 17084083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a quantitative cell-based bioassay for comparing the pharmacokinetic profiles of two recombinant erythropoietic proteins in serum.
    Wei X; Grill DS; Heatherington AC; Swanson SJ; Gupta S
    J Pharm Biomed Anal; 2007 Jan; 43(2):666-76. PubMed ID: 16971087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mimicry of erythropoietin and interleukin-6 signalling by an antibody/cytokine receptor chimera in murine myeloid 32D cells.
    Kawahara M; Ueda H; Tsumoto K; Kumagai I; Nagamune T
    J Biochem; 2007 Apr; 141(4):563-71. PubMed ID: 17442704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed.
    Palumbo C; Battisti S; Carbone D; Albonici L; Alimandi M; Bei R; Modesti A
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):893-901. PubMed ID: 17922127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of erythropoietin and its receptor in neuroblastomas.
    Sartelet H; Fabre M; Castaing M; Bosq J; Racu I; Lagonotte E; Scott V; Lecluse Y; Barette S; Michiels S; Vassal G
    Cancer; 2007 Sep; 110(5):1096-106. PubMed ID: 17647284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivalency - a way to enhance binding avidities and bioactivity - preliminary applications to EPO.
    Vadas O; Rose K
    J Pept Sci; 2007 Sep; 13(9):581-7. PubMed ID: 17631671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation and inhibition of the erythropoietin receptor by a membrane-anchored erythropoietin.
    Negre O; Fusil F; Henri A; Villette JM; Leboulch P; Beuzard Y; Payen E
    Exp Hematol; 2008 Apr; 36(4):412-23. PubMed ID: 18295963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone peptidomimetics: seeing double.
    Braisted A
    Nat Biotechnol; 1997 Nov; 15(12):1244-5. PubMed ID: 9359102
    [No Abstract]   [Full Text] [Related]  

  • 9. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.
    Park H; Kim YJ; Hahn JS
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6345-9. PubMed ID: 17869098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New scaffolds for the design of selective estrogen receptor modulators.
    Martín-Santamaría S; Rodríguez JJ; de Pascual-Teresa S; Gordon S; Bengtsson M; Garrido-Laguna I; Rubio-Viqueira B; López-Casas PP; Hidalgo M; de Pascual-Teresa B; Ramos A
    Org Biomol Chem; 2008 Oct; 6(19):3486-96. PubMed ID: 19082149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and characterization of a novel inhibitor of CDC25B, LGH00045.
    Feng X; Wang LN; Zhou YY; Yu HP; Shen Q; Zang Y; Zhou YB; Li JY; Zhang HX; Li J
    Acta Pharmacol Sin; 2008 Oct; 29(10):1268-74. PubMed ID: 18817634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
    Iljin K; Ketola K; Vainio P; Halonen P; Kohonen P; Fey V; Grafström RC; Perälä M; Kallioniemi O
    Clin Cancer Res; 2009 Oct; 15(19):6070-8. PubMed ID: 19789329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Importance of quality in biotechnology: the case of the first biological similarity of erythropoietin].
    Le Cotonnec JY; Lawny F
    Nephrol Ther; 2009 Feb; 5 Spec No1():10-5. PubMed ID: 19233077
    [No Abstract]   [Full Text] [Related]  

  • 14. Characterization of new multimeric erythropoietin receptor agonists.
    Vadas O; Hartley O; Rose K
    Biopolymers; 2008; 90(4):496-502. PubMed ID: 18273892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists.
    Manera C; Saccomanni G; Adinolfi B; Benetti V; Ligresti A; Cascio MG; Tuccinardi T; Lucchesi V; Martinelli A; Nieri P; Masini E; Di Marzo V; Ferrarini PL
    J Med Chem; 2009 Jun; 52(12):3644-51. PubMed ID: 19435366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin does not attenuate cytokine production and inflammation in microglia--implications for the neuroprotective effect of erythropoietin in neurological diseases.
    Wilms H; Schwabedissen B; Sievers J; Lucius R
    J Neuroimmunol; 2009 Jul; 212(1-2):106-11. PubMed ID: 19464738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin receptors on tumor cells: what do they mean?
    Fandrey J
    Oncologist; 2008; 13 Suppl 3():16-20. PubMed ID: 18458120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin in cardioprotection: does it have a future or is it all in the past?
    Mehta JL
    Cardiovasc Res; 2008 Sep; 79(4):549-50. PubMed ID: 18583337
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer.
    Saintigny P; Besse B; Callard P; Vergnaud AC; Czernichow S; Colombat M; Girard P; Validire P; Breau JL; Bernaudin JF; Soria JC
    Clin Cancer Res; 2007 Aug; 13(16):4825-31. PubMed ID: 17699861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of the new pseudo-symmetrical tamoxifen derivatives and their anti-tumor activity.
    Shiina I; Sano Y; Nakata K; Kikuchi T; Sasaki A; Ikekita M; Hasome Y
    Bioorg Med Chem Lett; 2007 May; 17(9):2421-4. PubMed ID: 17346960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.